Evaluation of Antihyperlipidemic Potential of Drakshasava Prepared by Traditional and Modern Methods in Hyperlipidemic Rats

The objective of the present study was to evaluate the lipid peroxidation activity and related antihyperlipidemic activity of Drakshasava-T and Drakshasava-M prepared by traditional and modern methods and its marketed formulation in high fat diet induced hyperlipidemic rats. The antioxidant activity of Drakshasava-T and Drakshasava-M was increased in concentration dependent manner. Drakshasava-T and Drakshasava-M inhibited the ferrous sulphate induced lipid peroxidation in a dose dependent manner and showed inhibitory concentration (IC₅₀) value 212.50 and 220.15 μg/ml respectively. Oral administration of Drakshasava-T and Drakshasava-M for nine weeks at the dose of 2 ml/kg significantly reduced serum cholesterol, serum LDL and serum triglycerides while showed significant rise in serum HDL as compared to high fat diet fed control group. Marketed Drakshasava also showed significant decrease in serum cholesterol, serum LDL, serum triglycerides and showed significant rise in serum HDL. Atorvastatin (1.2 mg/kg, p.o.) was used as standard antihyperlipidemic drug. Both types of Drakshasava as Drakshasava-T and Drakshasava-M showed significant reduction in atherogenic index as compared to high fat diet fed control group which strongly supports antiatherosclerotic property of Drakshasava.